

Prof Xenofon Baraliakos
Professor Xenofon Baraliakos is the Head of Rheumatology at the Rheumazentrum Ruhrgebiet, Herne, Germany, and Professor for Internal Medicine and Rheumatology at the Ruhr-University Bochum, Germany.
He studied human medicine at the University of Magdeburg, Berlin, Germany, and received his PhD degree in 2005. Professor Baraliakos was awarded his official Board Degree in orthopaedic surgery in 2007, and in internal medicine and rheumatology in 2014. His research interests include clinical and academic research in the field of spondyloarthritis, with special emphasis on imaging outcomes and treatment of the disease.
Among others, Professor Baraliakos won the European Workshop for Rheumatology Research (EWRR) Award in 2005, the European Alliance of Associations for Rheumatology (EULAR) Young Investigator Award in 2006 and 2008, the German Patient’s AS Society Award in 2010 and the Award for Excellence in Clinical Research from the European Society for Clinical Investigations (ESCI) in 2014.
Professor Baraliakos is the current president of the Assessment of Spondyloarthritis International Society (ASAS) and past Chair of the EULAR standing committee for musculoskeletal imaging. He also acts as a reviewer and is an associate editor in a number of major rheumatological journals.
Achieving MDA or DAPSA treatment targets improves quality of life for patients with PsA.1–4 Explore the characteristics of patients who report treatment success...
ASDAS and BASDAI are commonly used in clinical practice.1,2 However, discover recent studies demonstrating that a high proportion of real-world patients do not...
Explore which treatment targets may be more appropriate for making treatment decisions in axSpA.
PsA and axSpA have overlapping disease manifestations which are driven by inflammation.1 Explore several extracellular cytokines that are implicated in these...
Watch Prof Frank Behrens discuss the importance of treating skin symptoms in addition to musculoskeletal symptoms for patients with SpA.
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...